Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL | MicrobiomeTrials← Back to trialsNCT07692399
Safety and Efficacy of Edaravone Dexborneol Sublingual Tablets for Blood-Brain Barrier Dysfunction in CADASIL
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07Est. Completion: 2027-12
Enrollment target: 60 participants Locations- Huashan Hospital, Fudan University, Shanghai, China
Other microbiome trials you might be interested in
Cardiovascular DiseaseArterial StiffnessGermline Mutation in the NOTCH 3 GenePathogenesis of CADASILClinical Phenotype of CADASIL
Background:
CADASIL (cerebral autosomal dominant arteriopathy with subcortical infarct and leukoencephalopathy) is a ge…
Bethesda, United StatesEst. completion Jun 1, 2034
Germline Mutation in the NOTCH 3 GeneCardiovascular DiseaseArterial StiffnessPathogenesis of CADASILClinical Phenotype of CADASIL
Cerebral autosomal dominant arteriopathy with subcortical infarct (CADASIL) is a lethal disease caused by a gene mutatio…
Bethesda, United StatesCompleted May 3, 2022